

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 29 June 2020 (the “**Prospectus**”) issued by Immunotech Biopharm Ltd (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of each jurisdiction where those offers and sales occur. There will not be and is not currently intended to be any public offering of securities of the Company in the United States.

In connection with the Global Offering, CCB International Capital Limited, as stabilising manager (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilising or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it to conduct any such stabilising action, which, if commenced, may be discontinued at any time at the Stabilising Manager’s sole discretion. Any such stabilising activity is required to be brought to an end on Sunday, 2 August 2020, being the 30th day after the last day for lodging of applications under the Hong Kong Public Offering. Such stabilisation action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilising action cannot be taken to support the price of the Shares for longer than the stabilisation period which begins on the Listing Date and is expected to expire on Sunday, 2 August 2020, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, no further stabilising action may be taken, and demand for the Shares and the price of the Shares could fall. Reference is made to the clarification announcement of the Company dated 29 June 2020 in relation to the expiry date of the stabilisation period as stated in section headed “Structure of the Global Offering — 1. The Global Offering — Stabilisation” of the Prospectus.

Potential investors of the Offer Shares should note that the Joint Representatives (for themselves and on behalf of the Hong Kong Underwriters) are entitled to terminate the Hong Kong Underwriting Agreement upon giving notice in writing to the Company if any of the events set out in the section headed “Underwriting — Underwriting Arrangements — Hong Kong Underwriting Agreement — Grounds for termination” in the Prospectus occurs at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Friday, 10 July 2020).



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 100,000,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 50,000,000 Shares (as adjusted after reallocation)
Number of International Offer Shares	: 50,000,000 Shares (as adjusted after reallocation and subject to the Over-allotment Option)
Offer Price	: HK\$11.00 per Share plus brokerage of 1%, SFC transaction levy of 0.0027% and the Hong Kong Stock Exchange trading fee of 0.005%
Nominal value	: US\$0.001 per Share
Stock code	: 6978

Joint Sponsors



Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers



CMS 招商證券國際

中銀證券
CHINA SECURITIES COMPANY LIMITED

安信國際
ESSENCE INTERNATIONAL

農銀國際
ABC INTERNATIONAL

交銀國際
BOCOM International

申萬宏源香港
SHENWAN HONGYUAN

中融平和證券有限公司
ZHONGRONG PH SECURITIES LIMITED

中泰國際
ZTONGJI INTERNATIONAL

Joint Bookrunners and Joint Lead Managers